We are live on ! Find out more
FIS

FCPM III Services Portfolio holdings

AUM $722M
1-Year Est. Return 73.61%
This Fund
S&P 500
This Quarter Est. Return
+26.88%
1 Year Est. Return
+73.61%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$763M
AUM Growth
+$262M
Cap. Flow
+$140M
Cap. Flow %
18.38%
Top 10 Hldgs %
100%
Holding
11
New
2
Increased
3
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
VOR icon
Vor Biopharma
VOR
+$60.3M
2
MPLT
MapLight Therapeutics
MPLT
+$54.1M
3
RAPT
RAPT Therapeutics
RAPT
+$46.2M
4
CBIO
Crescent Biopharma
CBIO
+$21.4M
5
BCYC
Bicycle Therapeutics
BCYC
+$119K

Top Sells

Rank Stock Value
1
ATXS
Astria Therapeutics
ATXS
+$29.9M
2
REPL icon
Replimune Group
REPL
+$11.5M
3
NAMS icon
NewAmsterdam Pharma
NAMS
+$491K

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMS icon
1
NewAmsterdam Pharma
NAMS
$3.47B
$323M 42.3%
9,198,900
-13,484
-0.1% -$491K
DYN icon
2
Dyne Therapeutics
DYN
$3.88B
$107M 14.01%
5,462,846
– –
ENGN icon
3
enGene Therapeutics
ENGN
$125M
$87M 11.4%
9,632,561
– –
RAPT
4
DELISTED
RAPT Therapeutics
RAPT
$62.1M 8.14%
1,833,333
+1,489,096
+433% +$46.2M
MPLT
5
MapLight Therapeutics
MPLT
$1.63B
$56.7M 7.43%
+3,226,400
New +$54.1M
VOR icon
6
Vor Biopharma
VOR
$946M
$47.3M 6.2%
3,617,354
+3,237,714
+853% +$60.3M
REPL icon
7
Replimune Group
REPL
$882M
$27.3M 3.58%
2,808,368
-1,350,000
-32% -$11.5M
BCYC
8
Bicycle Therapeutics
BCYC
$290M
$24.6M 3.22%
3,468,430
+16,100
+0.5% +$119K
CBIO
9
Crescent Biopharma
CBIO
$537M
$19.9M 2.61%
+1,677,852
New +$21.4M
ENGNW icon
10
enGene Therapeutics Warrants
ENGNW
$3.53M
$8.52M 1.12%
2,878,148
– –
ATXS
11
DELISTED
Astria Therapeutics
ATXS
– –
-4,107,537
Closed -$29.9M

Similar funds

ZDA
Zweig-DiMenna Associates New York $722M AUM 97.69% 1-Year Est. Return
ZAM
Zevin Asset Management Boston, Massachusetts $723M AUM 15.62% 1-Year Est. Return
AF
Apollon Financial Mount Pleasant, South Carolina $723M AUM 24.23% 1-Year Est. Return
UW
Unique Wealth Clearwater, Florida $723M AUM 16.35% 1-Year Est. Return
PPW
Pasadena Private Wealth Pasadena, California $723M AUM 18.72% 1-Year Est. Return
VCM
Vivaldi Capital Management Chicago, Illinois $723M AUM 30.89% 1-Year Est. Return
FFM
FengHe Fund Management Singapore $724M AUM 196.18% 1-Year Est. Return
WLIM
White Lighthouse Investment Management Bedford, Massachusetts $721M AUM 16.12% 1-Year Est. Return

FCPM III Services's Q4 2025 Portfolio in Review

As of Q4 2025, FCPM III Services held 11 positions worth $763M, up 52% from $500M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

FCPM III Services deployed $140M of net new capital in Q4 2025, opening 2 new positions and adding to 3 existing holdings. Its largest new stake was MapLight Therapeutics: 3,226,400 shares worth $56.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Replimune Group, an estimated $11.5M trimmed.

  • FCPM III Services's largest Q4 2025 buy was MapLight Therapeutics: 3,226,400 shares worth $56.7M.
  • FCPM III Services added most to Vor Biopharma in Q4 2025, an estimated $60.3M increase.
  • FCPM III Services's biggest Q4 2025 reduction was Replimune Group, cutting an estimated $11.5M.
  • FCPM III Services fully exited Astria Therapeutics in Q4 2025, selling an estimated $29.9M.
  • FCPM III Services's ten largest holdings make up 100% of its $763M portfolio in Q4 2025.
  • FCPM III Services opened 2 new positions and closed 1 in Q4 2025.
  • FCPM III Services's portfolio value rose 52% quarter-over-quarter to $763M.

Based on FCPM III Services's 13F filing for Q4 2025, filed 17 Feb 2026.